Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UCB Sells S Asia Established Drugs Business To Dr. Reddy’s

This article was originally published in PharmAsia News

Executive Summary

Belgium’s UCB will sell its established products business in India to Dr. Reddy’s Labs – a move it said will help it grow its innovative neurology drugs portfolio. The Indian company expects to gain an edge in areas like respiratory, dermatology and pediatrics.

You may also be interested in...

Two Concerta Generics Lose Therapeutic Equivalency Rating

FDA downgrades Mallinckrodt and Kudco’s methylphenidate generics from AB- to BX-rated. An influx of patient complaints about lack of efficacy spurred an investigation of the products and subsequent revision of the agency’s draft bioequivalence guidelines for the ADHD drug.

Indian Investors Turn Cautious On Compliance Concerns

A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.

Lee Takes India Compulsory License Fight To Saxagliptin

In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts